X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR), focused on rare immune system diseases, announces its participation in the 36th Annual Piper Sandler Healthcare Conference in New York. The company will engage in a fireside chat on Tuesday, December 3, 2024, at 11:00 AM ET at the Lotte New York Palace. The event will be available via webcast through X4's investor relations website, with a replay option post-conference. Management will also be available for one-on-one meetings with investors, which can be arranged through Piper Sandler representatives.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, XFOR gained 4.98%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the 36th Annual Piper Sandler Healthcare Conference, taking place in New York, NY on December 3-5, 2024.
| 36th Annual Piper Sandler Healthcare Conference | |
| Date: | Tuesday, December 3, 2024 |
| Time: | 11:00AM ET |
| Format: | Fireside Chat |
| Location: | Lotte New York Palace, New York |
| Webcast Link | |
This live webcast will also be accessible through “events & presentations” page of the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a replay of this webcast will be available through the same link.
The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Piper Sandler representative to request meetings.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is X4 Pharmaceuticals (XFOR) presenting at the Piper Sandler Healthcare Conference 2024?
Where can I watch X4 Pharmaceuticals' (XFOR) Piper Sandler Conference presentation?
What type of presentation will XFOR give at the 2024 Piper Sandler Healthcare Conference?
How can investors arrange meetings with X4 Pharmaceuticals (XFOR) at the Piper Sandler Conference?
